Proto Labs, Inc. (PRLB)
Industrials · Metal Fabrication · NYSE
Proto Labs, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $298.06M | $344.49M | $445.60M | $458.73M | $434.39M | $488.10M | $488.40M | $503.88M | $500.89M | $533.13M |
| Gross profit | $166.94M | $193.84M | $238.68M | $235.29M | $217.83M | $222.69M | $215.47M | $221.99M | $223.20M | $237.14M |
| Net income | $42.71M | $51.78M | $76.59M | $63.66M | $50.87M | $33.37M | $-103.46M | $17.22M | $16.59M | $21.24M |
| Net margin | 14.3% | 15.0% | 17.2% | 13.9% | 11.7% | 6.8% | -21.2% | 3.4% | 3.3% | 4.0% |
Source: Proto Labs, Inc. SEC filings (10-K). 16 years of history available in the interactive view.
What growth is priced into PRLB stock?
At today's market cap of $1.77B, Proto Labs, Inc. is priced for free-cash-flow growth of about 13.1% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $59.66M from the FY ending 2025-12-31). For comparison, free cash flow actually grew -0.1%/yr over the last five fiscal years and revenue 4.2%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 16 years of Proto Labs, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track PRLB in your portfolio →
Proto Labs, Inc. financial history by metric
About Proto Labs, Inc.
Proto Labs, Inc., together with its subsidiaries, operates as a digital manufacturer of custom parts in the United States and Europe. It offers manufacturing services, such as molding, computer numerical control machining, 3D printing, and sheet metal to developers, engineers, and supply chain teams. The company was incorporated in 1999 and is headquartered in Maple Plain, Minnesota.
Proto Labs, Inc. — frequently asked questions
What is Proto Labs, Inc.'s revenue?
Proto Labs, Inc. (PRLB) reported revenue of $533.13M for fiscal year 2025, up 6.4% from the prior year, according to its SEC filings.
Is Proto Labs, Inc. profitable?
Yes. PRLB earned net income of $21.24M in fiscal 2025, a net margin of 4.0%.
What is PRLB's P/E ratio?
Proto Labs, Inc. trades at a price-to-earnings ratio of about 70.1 based on the latest data in our nightly-refreshed cache.
How fast is Proto Labs, Inc. growing?
PRLB's revenue grew at roughly 4.2% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Proto Labs, Inc. have?
As of fiscal year 2025, PRLB carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Proto Labs, Inc.'s gross margin?
PRLB's gross margin was 44.5% in fiscal 2025 — gross profit of $237.14M on revenue of $533.13M.
What is Proto Labs, Inc.'s market cap?
Proto Labs, Inc. (PRLB) has a market capitalization of about $1.77B, based on the latest data in our nightly-refreshed cache.
When does Proto Labs, Inc.'s fiscal year end?
PRLB's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into PRLB stock?
At today's market cap of $1.77B, Proto Labs, Inc. is priced for free-cash-flow growth of about 13.1% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $59.66M from the FY ending 2025-12-31). For comparison, free cash flow actually grew -0.1%/yr over the last five fiscal years and revenue 4.2%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Proto Labs, Inc.'s official SEC filings (10-K and 10-Q), covering 16 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.